SEC Filing Summary: Revelation Biosciences, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Revelation Biosciences, Inc., a Delaware corporation, on January 10, 2023, covering the event date of January 9, 2023. The company is an emerging growth company with principal executive offices in San Diego, California. Its securities, including common stock (REVB), units (REVBU), and redeemable warrants (REVBW), trade on The NASDAQ Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a disclosure of a corporate presentation rather than a financial statement update.
Material Changes
There are no material changes to financial performance or operational status reported in this document. The sole material event is the public release of an updated corporate presentation.
Guidance, Outlook, and Management Commentary
On January 9, 2023, the company made an updated corporate presentation available to the public, attached as Exhibit 99.1. The filing explicitly states that the information contained in Item 7.01 and Exhibit 99.1 is not treated as "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section. Consequently, this information will not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Corporate Presentation dated January 9, 2023) for specific operational updates and strategic outlook.
- Verify the exercise price of redeemable warrants, which is stated as $11.50 per share.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Note that the presentation content is not legally "filed" for liability purposes under Section 18 of the Exchange Act.